Creative Medical Technology Holdings Inc (CELZ)
4.395
-0.16
(-3.41%)
USD |
NASDAQ |
May 03, 16:00
4.395
0.00 (0.00%)
After-Hours: 20:00
Creative Medical Technology Holdings Research and Development Expense (Quarterly): 0.3494M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.3494M |
| September 30, 2023 | 0.9927M |
| June 30, 2023 | 0.3095M |
| March 31, 2023 | 0.319M |
| December 31, 2022 | 5.368M |
| September 30, 2022 | 0.2309M |
| June 30, 2022 | 0.6597M |
| March 31, 2022 | 0.01M |
| December 31, 2021 | 0.05M |
| September 30, 2021 | 0.0592M |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | |
| March 31, 2020 |
| Date | Value |
|---|---|
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | 0.0863M |
| September 30, 2018 | 0.0029M |
| June 30, 2018 | 0.0042M |
| March 31, 2018 | 0.0032M |
| December 31, 2017 | 0.0873M |
| September 30, 2017 | 0.0877M |
| June 30, 2017 | 0.0252M |
| March 31, 2017 | 0.0598M |
| December 31, 2016 | 0.0178M |
| September 30, 2016 | 0.0452M |
| June 30, 2016 | 0.018M |
| March 31, 2016 | 0.0044M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
Sep 2020
5.368M
Maximum
Dec 2022
0.5963M
Average
0.1451M
Median
Research and Development Expense (Quarterly) Benchmarks
| Avid Bioservices Inc | -- |
| Viking Therapeutics Inc | 24.10M |
| Avinger Inc | 1.152M |
| Aptevo Therapeutics Inc | 3.591M |
| Absci Corp | 12.27M |